Tumours often become resistant to treatment, but how this occurs is poorly understood. An analysis of how the protein Rb affects tumour growth and the response to therapy might cast light on the problem.
Researchers performed the first comprehensive analysis of the genes altered in individual brain cells of patients with Alzheimer’s disease, allowing them to identify the distinctive cellular pathways affected in neurons and other types of brain cells.
ViiV Healthcare has submitted a new drug application to the US Food and Drug Administration (FDA) for the first ever monthly, injectable, two-drug regimen of cabotegravir and Edurant (rilpivirine) for treatment of HIV.
The US Food and Drug Administration (FDA) has accepted a new drug application for review and granted priority review for darolutamide.